Ismael Ricardo Barosso

Dr. Ismael Ricardo Barosso

Instituto de Fisiología Experimental (IFISE)-CONICET, Rosario, Santa Fe, Argentina
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2018 in Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
Verified
Journal Article
Closed access
GMGisel S. Miszczuk
Gisel S. Miszczuk
Ismael Ricardo BarossoIsmael Ricardo Barosso
Ismael Ricardo Barosso
MLMaría Cecilia Larocca
María Cecilia Larocca
JMJulieta Marrone
Julieta Marrone
RMRaúl A. Marinelli
Raúl A. Marinelli
FCFernando A. Crocenzi
Fernando A. Crocenzi

1 October 2019 in Biochemical Pharmacology
Verified
Journal Article
Closed access
MRMaría Valeria Razori
María Valeria Razori
PMPaula M. Maidagan
Paula M. Maidagan
NCNadia Ciriaci
Nadia Ciriaci
RARomina B. Andermatten
Romina B. Andermatten
Ismael Ricardo BarossoIsmael Ricardo Barosso
Ismael Ricardo Barosso
MRMarcelo Gabriel Roma
Marcelo Gabriel Roma

2 December 2016 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
FTFlavia D. Toledo
Flavia D. Toledo
CBCecilia L. Basiglio
Cecilia L. Basiglio
Ismael Ricardo BarossoIsmael Ricardo Barosso
Ismael Ricardo Barosso
ABAndrea C. Boaglio
Andrea C. Boaglio
AZANDRES ERNESTO ZUCCHETTI
ANDRES ERNESTO ZUCCHETTI
MRMarcelo Gabriel Roma
Marcelo Gabriel Roma
In previous studies, we showed that the pro-oxidant model agent tert-butyl hydroperoxide (tBuOOH) induces alterations in hepatocanalicular secretory function by activating Ca2+-dependent protein kinase C isoforms (cPKC), via F-actin disorganization followed by endocytic internalization of canalicular transporters relevant to bile formation (Mrp2, Bsep). Since mitogen-activated protein kinases (MAPKs) may be downstream effectors of cPKC, we investigated here the involvement of the MAPKs of the ERK1/2, JNK1/2, and p38MAPK types in these deleterious effects. tBuOOH (100 µM, 15 min) increased the proportion of the active, phosphorylated forms of ERK1/2, JNK1/2, and p38MAPK, and panspecific PKC inhibition with bisindolylmaleimide-1 (100 nM) or selective cPKC inhibition with Gö6976 (1 μM) prevented the latter two events. In isolated rat hepatocyte couplets, tBuOOH (100 µM, 15 min) decreased the canalicular vacuolar accumulation of the fluorescent Bsep and Mrp2 substrates, cholylglycylamido fluorescein, and glutathione-methylfluorescein, respectively, and selective inhibitors of ERK1/2 (PD098059), JNK1/2 (SP600125), and p38MAPK (SB203580) partially prevented these alterations. In in situ perfused rat livers, these three MAPK inhibitors prevented tBuOOH (75 µM)-induced impairment of bile flow and the decrease in the biliary output of the Bsep and Mrp2 substrates, taurocholate, and dinitrophenyl-S-glutathione, respectively. The changes in Bsep/Mrp2 and F-actin localization induced by tBuOOH, as assessed by (immuno)fluorescence staining followed by analysis of confocal images, were prevented total or partially by the MAPK inhibitors. We concluded that MAPKs of the ERK1/2, JNK1/2, and p38MAPK types are all involved in cholestasis induced by oxidative stress, by promoting F-actin rearrangement and further endocytic internalization of canalicular transporters critical for bile formation.

14 May 2019 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
MRMarcelo Gabriel Roma
Marcelo Gabriel Roma
Ismael Ricardo BarossoIsmael Ricardo Barosso
Ismael Ricardo Barosso
GMGisel S. Miszczuk
Gisel S. Miszczuk
FCFernando A. Crocenzi
Fernando A. Crocenzi
EPEnrique J. Sánchez Pozzi
Enrique J. Sánchez Pozzi
Bile flow generation is driven by the vectorial transfer of osmotically active compounds from sinusoidal blood into a confined space, the bile canaliculus. Hence, localization of hepatocellular transporters relevant to bile formation is crucial for bile secretion. Hepatocellular transporters are localized either in the plasma membrane or in recycling endosomes, from where they can be relocated to the plasma membrane on demand, or endocytosed when the demand decreases. The balance between endocytic internalization/ exocytic targeting to/from this recycling compartment is therefore the main determinant of the hepatic capability to generate bile, and to dispose endo- and xenobiotics. Furthermore, the exacerbated endocytic internalization is a common pathomechanisms in both experimental and human cholestasis; this results in bile secretory failure and, eventually, posttranslational transporter downregulation by increased degradation. This review summarizes the proposed structural mechanisms accounting for this pathological condition (e.g., alteration of function, localization or expression of F-actin or F-actin/transporter cross-linking proteins, and switch to membrane microdomains where they can be readily endocytosed), and the mediators implicated (e.g., triggering of “cholestatic” signaling transduction pathways). Lastly, we discussed the efficacy to counteract the cholestatic failure induced by transporter internalization of a number of therapeutic experimental approaches based upon the use of compounds that trigger exocytic targetting of canalicular transporters (e.g., cAMP, tauroursodeoxycholate). This therapeutics may complement treatments aimed to transcriptionally improve transporter expression, by affording proper localization and membrane stability to the de novo synthesized transporters.

12 July 2019 in Archives of Toxicology
Verified
Journal Article
Closed access
PDF file
RARomina Belén Andermatten
Romina Belén Andermatten
NCNadia Ciriaci
Nadia Ciriaci
VSVirginia Soledad Schuck
Virginia Soledad Schuck
NSNicolás Di Siervi
Nicolás Di Siervi
MRMaría Valeria Razori
María Valeria Razori
EPEnrique Juan Sánchez Pozzi
Enrique Juan Sánchez Pozzi

10 April 2024 in Biochimie
Verified
Journal Article
Closed access
GSGimena Salas
Gimena Salas
ALAlen A. Litta
Alen A. Litta
AMAnabela C. Medeot
Anabela C. Medeot
VSVirginia S. Schuck
Virginia S. Schuck
RARomina B. Andermatten
Romina B. Andermatten
FCFernando A. Crocenzi
Fernando A. Crocenzi